title: A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
abstract: Fourteen patients with malignant nondysgerminomatous germ-cell tumors of the ovary were treated with a combination of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen). Nine patients received PVeBV as primary postoperative therapy, of whom four had no residual disease. Four patients received PVeBV for recurrent disease. One patient underwent PVeBV therapy as second-line treatment. Three patients with initial poor prognostic features were treated with early high-dose chemotherapy with autologous bone marrow rescue as consolidation therapy after two cycles of PVeBV. Ten of 14 patients (71%) are progression-free with a median follow-up of 6 year. Equal efficacy and less toxicity favor the combination of bleomycin, etoposide, and cisplatin (BEP) as standard treatment of ovarian germ-cell tumors in the 1990s.
authors.affiliation: Department of Medicine, Institut Gustave-Roussy, Villejuif, France.
authors.forename: S
authors.initials: S
authors.lastname: Culine
authors.forename: J
authors.initials: J
authors.lastname: Kattan
authors.forename: C
authors.initials: C
authors.lastname: Lhomme
authors.forename: P
authors.initials: P
authors.lastname: Duvillard
authors.forename: G
authors.initials: G
authors.lastname: Michel
authors.forename: D
authors.initials: D
authors.lastname: Castaigne
authors.forename: J
authors.initials: J
authors.lastname: Leclere
authors.forename: J
authors.initials: J
authors.lastname: Pico
authors.forename: J P
authors.initials: JP
authors.lastname: Droz
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D001761:Bleomycin / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D018237:Germinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D011379:Prognosis; D012086:Reoperation; D015996:Survival Rate; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014408:Biomarkers, Tumor; D001761:Bleomycin; D014747:Vinblastine; D005047:Etoposide; D002945:Cisplatin